title: E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.
abstract: The expressions of E2F1 and retinoblastoma protein (pRB) were analyzed in 165 lymph node-positive breast cancers. All patients underwent adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC). E2F1 was expressed in 43.6% and pRB was expressed in 46.1%. E2F1 expression was significantly increased in pRB-expressing tumors and was associated with an S-phase fraction. By univariate survival analyses, E2F1 expression and ER were identified as significant prognostic factors for disease recurrence and patient survival. E2F1 was the only significant prognostic factor of patient outcome after FAC chemotherapy by multivariate analysis.
authors.affiliation: Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, South Korea. shwhan@unitel.co.kr
authors.forename: Sehwan
authors.initials: S
authors.lastname: Han
authors.forename: Kyeongmee
authors.initials: K
authors.lastname: Park
authors.forename: Byung-Noe
authors.initials: BN
authors.lastname: Bae
authors.forename: Ki Hwan
authors.initials: KH
authors.lastname: Kim
authors.forename: Hong-Joo
authors.initials: HJ
authors.lastname: Kim
authors.forename: Young-Duck
authors.initials: YD
authors.lastname: Kim
authors.forename: Hong-Yong
authors.initials: HY
authors.lastname: Kim
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D018797:Cell Cycle Proteins; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004268:DNA-Binding Proteins; D004317:Doxorubicin / Q000008:administration & dosage; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; D005260:Female; D005434:Flow Cytometry; D005472:Fluorouracil / Q000008:administration & dosage; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000473:pathology*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000235:genetics / Q000378:metabolism; D015996:Survival Rate; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D011960:Receptors, Estrogen; D016160:Retinoblastoma Protein; D014157:Transcription Factors; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil